Outcomes of patients with heart failure after thrombectomy for ischemic stroke: A systematic review and meta-analysis.

Interv NeuroradiolApr 21, 2025 (epub)
Clinical ResearchCardiologyNeurologyOpen access

Gabriel Marinheiro, Gabriel de Almeida Monteiro, Ivo Queiroz et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared outcomes after mechanical thrombectomy (MT) for acute ischemic stroke in patients with and without heart failure (HF). Across 3587 patients, including 1187 with HF, HF was associated with higher 90-day mortality (RR 2.01; 95% CI: 1.33-3.03; p < 0.01) and a lower likelihood of favorable neurologic outcome (RR 0.76; 95% CI: 0.67-0.86; p < 0.01). Symptomatic intracranial hemorrhage and recanalization success did not differ notably. Findings in the reduced-LVEF subgroup were directionally similar.

Key findings

  • HF was associated with higher 90-day mortality after MT (RR 2.01; 95% CI: 1.33-3.03; p < 0.01).
  • Favorable neurologic outcome at 90 days was less likely in patients with HF (RR 0.76; 95% CI: 0.67-0.86; p < 0.01).
  • There was no notable difference in symptomatic intracranial hemorrhage (RR 1.57; 95% CI: 0.98-2.51; p = 0.06) or recanalization success (RR 1.02; 95% CI: 0.98-1.07; p = 0.28).
  • Among patients with reduced LVEF, HF was associated with higher mortality (RR 1.91; 95% CI: 1.05-3.49; p = 0.03) and worse functional outcomes (RR 0.83; 95% CI: 0.72-0.95; p < 0.01).

Why it matters

The findings indicate that HF identifies a group with poorer prognosis after thrombectomy, even though procedural recanalization and symptomatic bleeding were not notably different. This distinction may help frame outcome expectations and underscores the importance of considering cardiac comorbidity when interpreting post-stroke recovery. The pooled associations do not establish that HF itself causes the poorer outcomes.

What to keep in mind

The abstract does not report the number or design of included studies, and the pooled comparisons are observational; residual differences between patients with and without HF may contribute to the associations.

Source

Published in Interv Neuroradiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.